EP1367987A2 - Utilisation de combinaisons d'agents actifs composees d'acide alpha-liponique et de substances dermatologiquement acceptables presentant une absorption de lumiere dans la gamme des uv-a et uv-b, pour la fabrication de preparations cosmetiques et dermatologiques - Google Patents

Utilisation de combinaisons d'agents actifs composees d'acide alpha-liponique et de substances dermatologiquement acceptables presentant une absorption de lumiere dans la gamme des uv-a et uv-b, pour la fabrication de preparations cosmetiques et dermatologiques

Info

Publication number
EP1367987A2
EP1367987A2 EP02729959A EP02729959A EP1367987A2 EP 1367987 A2 EP1367987 A2 EP 1367987A2 EP 02729959 A EP02729959 A EP 02729959A EP 02729959 A EP02729959 A EP 02729959A EP 1367987 A2 EP1367987 A2 EP 1367987A2
Authority
EP
European Patent Office
Prior art keywords
polyethylene glycol
skin
acid
ether
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02729959A
Other languages
German (de)
English (en)
Inventor
Claudia Mundt
Jens Schulz
Uwe SCHÖNROCK
Rainer Wolber
Inge Kruse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP1367987A2 publication Critical patent/EP1367987A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4966—Triazines or their condensed derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to cosmetic or dermatological preparations containing active ingredients for the care and protection of the skin, in particular sensitive skin, as well as very particularly in the foreground for skin aged or aging due to intrinsic and / or extrinsic factors, and the use of such active ingredients and combinations such active ingredients in the field of cosmetic and dermatological skin care.
  • Cosmetic skin care is understood primarily to mean that the natural function of the skin as a barrier against environmental influences (eg dirt, chemicals, microorganisms) and against the loss of the body's own substances (eg water, natural fats, electrolytes) is strengthened or restored ,
  • the barrier effect of the skin can be quantified by determining the transepidermal water loss (TEWL - transepidermal water loss). This is the evaporation of water from the inside of the body without taking into account the loss of water when sweating.
  • the determination of the TEWL value has proven to be extremely informative and can be used to diagnose cracked or chapped skin, to determine the compatibility of chemically differently structured surfactants and the like.
  • Chronological skin aging is e.g. caused by endogenous, genetically determined factors. In the epidermis and dermis it occurs due to aging e.g. the following structural damage and malfunctions, which may also fall under the term "senile xerosis":
  • Exogenous factors such as UV light and chemical pollutants, can be cumulative and e.g. accelerate or complement the endogenous aging processes.
  • exogenous factors e.g. the following structural damage and functional disorders in the skin that go beyond the extent and quality of the damage with chronological aging:
  • the present invention relates in particular to products for the care of naturally aged skin and for the treatment of the consequential damage caused by light aging, in particular the phenomena listed under a) to g).
  • Products for the care of aged skin are known per se. They contain e.g. Retinoids (vitamin A acid and / or its derivatives) or vitamin A and / or its derivatives.
  • Retinoids vitamin A acid and / or its derivatives
  • their impact on structural damage is limited in scope.
  • the use of products containing vitamin A acid often causes severe erythematous skin irritation. Retinoids can therefore only be used in low concentrations.
  • the present invention relates to cosmetic preparations with effective protection against harmful oxidation processes in the skin, but also to protect cosmetic preparations themselves or to protect the constituents of cosmetic preparations from harmful oxidation processes.
  • the present invention further relates to antioxidants, preferably those which are used in skin-care cosmetic or dermatological preparations.
  • the invention also relates to cosmetic and dermatological preparations containing such antioxidants.
  • the present invention relates to cosmetic and dermatological preparations for the prophylaxis and treatment of cosmetic or dermatological skin changes such as e.g. skin aging, especially skin aging caused by oxidative processes.
  • the present invention relates to active substances and preparations containing such active substances for cosmetic and dermatological treatment or prophylaxis of erythematous, inflammatory, allergic or autoimmune-reactive symptoms, in particular dermatoses.
  • the present invention relates to active ingredient combinations and preparations which are used for the prophylaxis and treatment of light-sensitive skin, in particular photodermatoses.
  • UVC range rays with a wavelength shorter than 290 nm
  • UVB range rays in the range between 290 nm and 320 nm, the so-called UVB range, cause erythema simple sunburn or even more or less severe burns.
  • the narrower range around 308 nm is given as a maximum of the erythema effectiveness of sunlight.
  • Numerous compounds are known for protection against UVB radiation, which are derivatives of 3-benzylidene camphor, 4-aminobenzoic acid, cinnamic acid, salicylic acid, benzophenone and also 2-phenylbenzimidazole.
  • UVA range It is also important to have filter substances available for the range between about 320 nm and about 400 nm, the so-called UVA range, since their rays can cause reactions in light-sensitive skin. It has been proven that UVA radiation leads to damage to the elastic and collagen fibers of the connective tissue, which causes the skin to age prematurely, and that it is to be seen as the cause of numerous phototoxic and photoallergic reactions. The damaging influence of UVB radiation can be intensified by UVA radiation.
  • UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products interfere with the skin's metabolism.
  • photochemical reaction products are predominantly radical compounds, for example hydroxyl radicals, singlet oxygen.
  • Undefined radical photo products which are created in the skin itself, can also display uncontrolled subsequent reactions due to their high reactivity.
  • singlet oxygen a non-radical excited state of the oxygen molecule can occur with UV radiation, just as short-lived epoxies and many others.
  • Singlet oxygen for example, is characterized by increased reactivity compared to the triplet oxygen normally present (radical ground state). However, there are also excited, reactive (radical) triplet states of the oxygen molecule.
  • UV radiation also belongs to ionizing radiation. There is therefore a risk that ionic species also develop when exposed to UV rays, which in turn can oxidatively intervene in the biochemical processes.
  • antioxidants and / or free radical scavengers can be incorporated into the cosmetic or dermatological formulations.
  • vitamin E a substance with a known antioxidative effect, in light protection formulations, but the effect achieved here also falls far short of the hoped-for effect.
  • the object of the invention was therefore also to provide cosmetic, dermatological and pharmaceutical active substances and preparations and light protection formulations which are used for the prophylaxis and treatment of light-sensitive skin, in particular photodermatoses, preferably PLD.
  • Antioxidants are mainly used as protective substances against the spoilage of the preparations containing them. Nevertheless, it is known that undesirable oxidation processes can also occur in human and animal skin. Such pro Processes play an essential role in skin aging.
  • antioxidants and / or free radical scavengers can be incorporated into cosmetic or dermatological formulations.
  • antioxidants and radical scavengers are known. It has already been proposed in US Pat. Nos. 4,144,325 and 4,248,861 and from numerous other documents to use vitamin E, a substance with a known antioxidant activity in light protection formulations, but the effect achieved here also falls far short of the hoped-for effect.
  • the object of the present invention was therefore to find ways which avoid the disadvantages of the prior art.
  • the effect of repairing the damage associated with endogenous, chronological and exogenous skin aging and the prophylaxis should be permanent, sustainable and without the risk of side effects.
  • an effective treatment but also a prophylaxis of deficient, sensitive or hypoactive skin conditions or deficient, sensitive or hypoactive conditions of skin appendages Symptoms of premature aging of the skin (eg wrinkles, age spots, telangiectasias) and / or the appendages of the skin, of environmental ones (smoking, smog, reactive oxygen species, free radicals) and in particular light-related negative changes in the skin and appendages.
  • the active ingredient according to the invention or cosmetic or topical dermatological preparations with an effective content of the active ingredient according to the invention also surprisingly serves to calm sensitive or irritated skin to stimulate collagen, hyaluronic acid, elastin synthesis to stimulate the ceramide synthesis of the skin to stimulate intracellular DNA synthesis, especially in deficient or hypoactive skin conditions.
  • the active ingredient combinations according to the invention act synergistically with respect to the individual components.
  • ⁇ -Lipoic acid was isolated from liver tissue in 1952 and its structure as a sulfur-containing fatty acid was elucidated. Bacteria, plants and higher organisms can produce ⁇ -lipoic acid in their metabolism themselves, for humans the question of their own biosynthesis is still open.
  • ⁇ -Lipoic acid is used to treat polyneuropathy, a sensory disorder on the hands and feet as a late consequence of diabetes. 200 to 600 milligrams of ⁇ -lipoic acid per day lead to a significant reduction in pain intensity. The energy metabolism of the hand and foot nerves is activated by ⁇ -lipoic acid, which leads to better nerve conductivity and thus less numbness and reflex failures.
  • ⁇ -Lipoic acid lowers pathologically increased liver values and promotes the healing of hepatitis. Most foods contain small amounts of ⁇ -lipoic acid, only relatively high levels can be found in meat. It is recognized that ⁇ -lipoic acid has strong antioxidant properties.
  • WO97 / 10808 and US Pat. No. 5,472,698 describe the cosmetic use of ⁇ -lipoic acid against symptoms of skin aging.
  • DE-42 42 876 describes active ingredient combinations of biotin and antioxidants with ⁇ -lipoic acid for cosmetic and / or dermatological care of the skin and / or the appendages of the skin as well as cosmetic and / or dermatological preparations containing such active ingredient combinations.
  • the preparations according to the invention advantageously contain 0.001 10% by weight of ⁇ -lipoic acid, based on the total weight of the preparations.
  • the preparations according to the invention contain substances which absorb UV radiation in the UV-A and / or UV-B range, the total amount of filter substances, for. B. 0.1 wt .-% to 30 wt .-%, preferably 0.5 to 20 wt .-%, in particular 1.0 to 15.0 wt .-%, based on the total weight of the preparations to cosmetic
  • 0.1 wt .-% to 30 wt .-% preferably 0.5 to 20 wt .-%, in particular 1.0 to 15.0 wt .-%, based on the total weight of the preparations to cosmetic
  • UV-A filter substances for the purposes of the present invention are dibenzoyl methane derivatives, in particular 4- (tert-butyl) -4'-methoxydibenzoyl methane (CAS No. 70356-09-1), which is available from Givaudan under the Parsol brand ® 1789 and is sold by Merck under the trade name Eusolex® 9020.
  • dibenzoyl methane derivatives in particular 4- (tert-butyl) -4'-methoxydibenzoyl methane (CAS No. 70356-09-1), which is available from Givaudan under the Parsol brand ® 1789 and is sold by Merck under the trade name Eusolex® 9020.
  • UV-A filter substances are phenylene-1,4-bis (2-benzimidazyl) -3,3'- 5,5'-tetrasulfonic acid
  • salts especially the corresponding sodium, potassium or triethanolammonium salts, in particular the phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid bis sodium salt
  • 1,4-di (2-oxo-10-sulfo-3-bomylidenemethyl) benzene and its salts especially the corresponding 10-sulfato compounds, especially the corresponding sodium, potassium or triethanolammonium salt
  • benzene-1,4-di (2-oxo-3-bornylidenemethyl-10-sulfonic acid is also called benzene-1,4-di (2-oxo-3-bornylidenemethyl-10-sulfonic acid
  • Advantageous UV filter substances in the sense of the present invention are also so-called broadband filters, i.e. Filter substances that absorb both UV-A and UV-B radiation.
  • Advantageous broadband filters or UV-B filter substances are, for example, bis-resorcinyltriazine derivatives with the following structure:
  • R, R 2 and R 3 are selected independently of one another from the group of branched and unbranched alkyl groups having 1 to 10 carbon atoms or a single represent hydrogen atom.
  • the 2,4-bis - ⁇ [4- (2-ethylhexyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) -1,3,5-triazine (INCl: aniso triazine) are particularly preferred ), which is available under the trade name Tinosorb® S from CIBA-Chemicals GmbH, and the 4,4 ', 4 "- (1,3,5-triazine-2,4,6-triyltriimino) -tris-benzoic acid- tris (2-ethylhexyl ester), synonymous: 2,4,6-tris [anilino- (p-carbo-2'-ethyl-1'-hexyloxy)] - 1,3,5-triazine (INCl:
  • UV filter substances which the structural motif
  • UV filter substances for the purposes of the present invention, for example the s-triazine derivatives described in European patent application EP 570 838 A1, the chemical structure of which is given by the generic formula
  • R represents a branched or unbranched dC s alkyl radical, a C 5 -C 2 cycloalkyl radical, optionally substituted by one or more dC 4 alkyl groups, represents an oxygen atom or an NH group, a branched or unbranched C 1 -C 8 alkyl radical, a C 5 -C 12 cycloalkyl radical, optionally substituted with one or more CC 4 alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula
  • A represents a branched or unbranched Ci-Cis-alkyl radical, a C5-C ⁇ 2 cycloalkyl or aryl radical, optionally substituted with one or more C.
  • R 3 represents a hydrogen atom or a methyl group
  • n represents a number from 1 to 10
  • a branched or unbranched CrC ⁇ 8 alkyl radical represents a C 5 -C ⁇ 2 cycloalkyl radical, optionally substituted with one or more dC - alkyl groups
  • X represents the NH group
  • a branched or unbranched C 8 -C alkyl radical represents a C 5 -C 12 cycloalkyl radical, optionally substituted with one or more CC 4 alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula
  • A represents a branched or unbranched C 1 -C 8 alkyl radical, a C 5 -C 12 cycloalkyl or aryl radical, optionally substituted by one or more C.
  • a particularly advantageous UV filter substance in the sense of the present invention is also an asymmetrically substituted s-triazine, the chemical structure of which is represented by the formula
  • dioctylbutylamidotriazon IRCl: Diocylbutamidotriazone
  • U VASORB HEB trade name U VASORB HEB from Sigma 3V.
  • European laid-open specification 775698 also describes bis-resorcinyltriazine derivatives which are to be used advantageously and whose chemical structure is represented by the generic formula
  • R-, R 2 and Ai represent a wide variety of organic radicals.
  • Also advantageous for the purposes of the present invention are 2,4-bis - ⁇ [4- (3-sulfonato) -2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) -1, 3,5-triazine sodium salt, the 2,4-bis - ⁇ [4- (3- (2-propyloxy) -2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) -1,3,5-triazine, the 2,4-bis - ⁇ [4- (2-ethylhexyloxy) -2-hydroxy] phenyl ⁇ -6- [4- (2-methoxyethylcarboxyl) phenylamino] -1,3,5-triazine , the 2,4-bis - ⁇ [4- (3- (2-propyloxy) -2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- [4
  • An advantageous broadband filter for the purposes of the present invention is 2,2'-methylene-bis- (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) -phenol) [INCl : Bisoctyltriazole], which is characterized by the chemical structural formula
  • Tinosorb® M is marked and is available under the trade name Tinosorb® M from CIBA Chemical GmbH.
  • Another advantageous broadband filter for the purposes of the present invention is 2- (2H-benzotriazol-2-yl) -4-methyl-6- [2-methyl-3- [1,3,3,3-tetramethyl-1 - [( trimethylsilyl) oxy] disiloxanyl] propyl] phenol (CAS No .: 155633-54-8) with the INCI name Drometrizole Trisiloxane, which is characterized by the chemical structural formula is marked.
  • the UV-B filters can be oil-soluble or water-soluble.
  • Advantageous oil-soluble UV-B filter substances are e.g. B .:
  • 3-benzylidene camphor derivatives preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl ester;
  • esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone
  • Advantageous water-soluble UV-B filter substances are e.g. B .:
  • ⁇ sulfonic acid derivatives of 3-benzylidene camphor such as. B. 4- (2-oxo-3-bornylidenemethyljbenzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidenemethyl) sulfonic acid and their salts.
  • a further light protection filter substance to be used advantageously according to the invention is ethylhexyl-2-cyano-3,3-diphenylacrylate (octocrylene), which is available from BASF under the name Uvinul ® N 539 and is characterized by the following structure:
  • preparations containing the active compound combinations according to the invention, customary antioxidants can be used.
  • the antioxidants are advantageously selected from the group consisting of amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (e.g. anserine), carotenoids, Carotenes (e.g. ⁇ -carotene, ß-carotene, lycopene) and their derivatives, aurothioglucose, propylthiouracil and other thiols (e.g.
  • amino acids e.g. glycine, histidine, tyrosine, tryptophan
  • imidazoles e.g. urocanic acid
  • peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (e.g
  • thioredoxin glutathione, cysteine, cystine and cystamine and their glycosyl, N-acetyl, methyl, ethyl, Propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides , Nucleosides and salts) and sulfoximine compounds (e.g.
  • buthioninsulfoximines homocysteine sulfoximine, buthioninsulfones, penta-, hexa-, heptathioninsulfoximine
  • very low tolerable dosages e.g. pmol to ⁇ mol / kg
  • metal chelators e.g. ⁇ -hydroxy fatty acids , Palmitic acid, phytic acid, Lactoferrin
  • ⁇ -hydroxy acids e.g. citric acid, lactic acid, malic acid
  • humic acid bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g.
  • ⁇ -linolenic acid linoleic acid, oleic acid
  • Folic acid and its derivatives alanine diacetic acid, flavonoids, polyphenols, catechins, vitamin C and derivatives (e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g.
  • vitamin E acetate vitamin E acetate
  • coniferyl benzoate of benzoin and its resin rutinic acid Derivatives, ferulic acid and its derivatives, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguajak resin acid, nordihydroguajaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (eg ZnO, ZnSO 4 ) selenium and its derivatives (eg selenium and its derivatives) , Stilbenes and their derivatives (for example stilbene oxide, trans-stilbene oxide) and the derivatives suitable according to the invention (salts, esters, ethers, Sugar, nucleotides, nucleosides, peptides and lipids) of these active ingredients.
  • stilbenes and their derivatives for example stilbene oxide, trans-stilbene oxide
  • the derivatives suitable according to the invention salts, esters
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 1 to 10% by weight, based on the total weight of the preparation ,
  • the prophylaxis or the cosmetic or dermatological treatment with the active ingredient used according to the invention or with the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is carried out in the usual way, in such a way that the applied active ingredient or the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is applied to the affected skin areas.
  • the active ingredient used according to the invention can advantageously be incorporated into customary cosmetic and dermatological preparations, which can be in various forms. So you can e.g. a solution, an emulsion of the type water-in-oil (W / O) or of the type oil-in-water (O / W), or a multiple emulsions, for example of the type water-in-oil-in-water (W / O / W) or oil-in-water-in-oil (O / W / O), a hydrodispersion or lipodispersion, a gel, a solid stick or an aerosol.
  • Emulsions according to the invention in the sense of the present invention are advantageous and contain e.g. Fats, oils, waxes and / or other fat bodies, as well as water and one or more emulsifiers, as are usually used for such a type of formulation.
  • the cosmetic preparations according to the invention can therefore contain cosmetic auxiliaries as are usually used in such preparations, e.g. Preservatives, bactericides, deodorizing substances, antiperspirants, insect repellents, vitamins, anti-foaming agents, dyes, pigments with a coloring effect, thickeners, softening substances, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components a cosmetic formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic auxiliaries as are usually used in such preparations, e.g. Preservatives, bactericides, deodorizing substances, antiperspirants, insect repellents, vitamins, anti-foaming agents, dyes, pigments with a coloring effect, thickeners, softening substances, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components a cosmetic formulation such as alcohols, polyols
  • Medical topical compositions in the sense of the present invention generally contain one or more drugs in effective concentration.
  • Cosmetic and dermatological preparations according to the invention advantageously also contain inorganic pigments based on metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular the oxides of titanium (TiO 2 ), zinc (ZnO), iron (eg Fe 2 O 3 ), zirconium (ZrO 2 ), silicon (SiO 2 ), manganese (e.g. MnO), aluminum (Al 2 O 3 ), cerium (e.g. Ce 2 O 3 ); Mixed oxides of the corresponding metals and mixtures of such oxides. Pigments based on TiO are particularly preferred.
  • the inorganic pigments are in hydrophobic form, i.e. that they have been treated to be water-repellent on the surface.
  • This surface treatment can consist in that the pigments are provided with a thin hydrophobic layer by methods known per se.
  • One such method consists, for example, in that the hydrophobic surface layer after a rectification
  • n and m are stoichiometric parameters to be used at will, R and R 'are the desired organic radicals.
  • hydrophobized pigments shown in analogy to DE-OS 33 14742 are advantageous.
  • Advantageous TiO 2 pigments are available, for example, under the trade names MT 100 T from TAYCA, M 160 from Kemira and T 805 from Degussa.
  • Preparations according to the invention can also contain anionic, nonionic and / or amphoteric surfactants, especially if crystalline or microcrystalline solids, for example inorganic micropigments, are to be incorporated into the preparations according to the invention.
  • Surfactants are amphiphilic substances that can dissolve organic, non-polar substances in water.
  • hydrophilic parts of a surfactant molecule are mostly polar functional groups, for example -COO " , -OSO 3 2" , -SO 3 " , while the hydrophobic parts generally represent non-polar hydrocarbon residues.
  • Surfactants are generally of type and charge of the hydrophilic part of the molecule. There are four groups:
  • Anionic surfactants generally have carboxylate, sulfate or sulfonate groups as functional groups. In an aqueous solution they form negatively charged organic ions in an acidic or neutral environment. Cationic surfactants are characterized almost exclusively by the presence of a quaternary ammonium group. In aqueous solution they form positively charged organic ions in an acidic or neutral environment. Amphoteric surfactants contain both anionic and cationic groups and accordingly behave like anionic or cationic surfactants in aqueous solution depending on the pH. They have a positive charge in a strongly acidic environment and a negative charge in an alkaline environment. In the neutral pH range, however, they are zwitterionic, as the following example should illustrate:
  • Non-ionic surfactants do not form ions in an aqueous medium.
  • acylglutamates for example sodium acylglutamate, di-TEA-palmitoylaspartate and sodium caprylic / capric glutamate,
  • acyl peptides for example palmitoyl-hydrolyzed milk protein, sodium cocoyl-hydrolyzed soy protein and sodium / potassium cocoyl-hydrolyzed collagen,
  • sarcosinates for example myristoyl sarcosin, TEA-lauroyl sarcosinate, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate,
  • taurates for example sodium lauroyl taurate and sodium methyl cocoyl taurate
  • carboxylic acids for example lauric acid, aluminum stearate, magnesium alkanolate and zinc undecylenate,
  • ester carboxylic acids for example calcium stearoyl lactylate, laureth-6 citrate and sodium PEG-4 lauramide carboxylate,
  • ether carboxylic acids for example sodium laureth-13 carboxylate and sodium PEG-6 cocamide carboxylate,
  • Phosphoric acid esters and salts such as DEA-oleth-10-phosphate and dilaureth-4-phosphate
  • acyl isethionates e.g. Sodium / ammonium cocoyl isethionate
  • alkylarylsulfonates 3. alkyl sulfonates, for example sodium coco monoglyceride sulfate, sodium C ⁇ 2 . ⁇ 4 olefin sulfonate, sodium lauryl sulfoacetate and magnesium PEG-3 cocamide sulfate,
  • Sulfosuccinates for example dioctyl sodium sulfosuccinate, disodium laureth sulfosuccinate, disodium lauryl sulfosuccinate and disodium undecylenamido MEA sulfosuccinate
  • sulfuric acid esters such as
  • alkyl ether sulfate for example sodium, ammonium, magnesium, MIPA, TIPA laureth sulfate, sodium myreth sulfate and sodium C ⁇ 2 - ⁇ 3 pareth sulfate,
  • Alkyl sulfates for example sodium, ammonium and TEA lauryl sulfate.
  • Quaternary surfactants contain at least one N atom which is covalently linked to 4 alkyl or aryl groups. Regardless of the pH value, this leads to a positive charge.
  • Alkyl betaine, alkyl amidopropyl betaine and alkyl amidopropyl hydroxysulfain are advantageous.
  • the cationic surfactants used in the invention can be also preferably selected from the group of quaternary ammonium compounds, in particular benzene zyltrialkylammoniumchloride or bromides, such as Benzyldimethylstea- rylammoniumchlorid, also alkyltrialkylammonium, such as for example Ce tyltrimethylammoniumchlorid or bromide, alkyldimethylhydroxyethylammonium chlorides or bromides, dialkyldimethylammonium chlorides or bromides, alkylamidethyltrimethylammonium ether sulfates, alkylpyridinium salts, for example lauryl or cetylpyrimidinium chloride, imidazoline derivatives and compounds with a cationic character, such as amine oxides, for example alkyldimethylamino oxides or alkylaminoethyldimethylamine oxides. Cetyltrimethylammoni
  • Amphoteric surfactants Amphoteric surfactants to be used advantageously
  • acyl / dialkyl ethylenediamine for example sodium acyl amphoacetate, disodium acyl amphodipropionate, disodium alkyl amphodiacetate, sodium acylamphohydroxypropyl sulfonate, disodium acylamphodiacetate and sodium acylamphopropionate,
  • N-alkylamino acids for example aminopropylalkylglutamide, alkylaminopropionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.
  • alkanolamides such as Cocamide MEA / DEA / MIPA
  • amine oxides such as cocoamidopropylamine oxide
  • esters which are formed by esterification of carboxylic acids with ethylene oxide, glycerol, sorbitan or other alcohols,
  • ethers for example ethoxylated / propoxylated alcohols, ethoxylated / propoxylated esters, ethoxylated / propoxylated glycerol esters, ethoxylated / propoxylated cholesterol, ethoxylated / propoxylated triglyceride esters, ethoxylated propoxylated lanolin, ethoxylated / propoxylated polysiloxanes, propoxylated POE ethers and alkylpolyglycosyl Lauryl glucoside, decyl glycoside and cocoglycoside.
  • the surface-active substance can be present in the preparations according to the invention in a concentration between 1 and 95% by weight, based on the total weight of the preparations.
  • the lipid phase of the cosmetic or dermatological emulsions according to the invention can advantageously be selected from the following group of substances: mineral oils, mineral waxes oils such as triglycerides of capric or caprylic acid, as well as natural oils such as castor oil;
  • Fats, waxes and other natural and synthetic fat bodies preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids; benzoates;
  • Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof.
  • the oil phase of the emulsions of the present invention is advantageously selected from the group of the esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length of 3 to 30 carbon atoms.
  • ester oils can then advantageously be selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononylisononanoate, 2-ethylhexyl, ethyl-2-ethylhexyl Hexyldecyl stearate, 2-octyldodecyl palmitate, oleyl oleate, olerlerucate, erucyl oleate, erucylerucate as well as synthetic, semi-synthetic and natural mixtures of such esters, e.g. Jojoba oil.
  • the oil phase can advantageously be chosen from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and also the fatty acid triglycerides, especially the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 carbon atoms.
  • the fatty acid triglycerides can, for example, advantageously be selected from the group of synthetic, semisynthetic and natural oils, for example olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like. Any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention. It may also be advantageous to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • synthetic, semisynthetic and natural oils for example olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like. Any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention. It may also be advantageous to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • the oil phase is advantageously chosen from the group consisting of 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 12 -alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether.
  • Particularly advantageous are mixtures of C ⁇ 2 . ⁇ 5 -AIkylbenzoat and 2-ethylhexyl, mixtures of C ⁇ 2 . ⁇ 5 -Alky! Benzoate and isotridecyl isononanoate and mixtures of C ⁇ second 15 alkyl benzoate, 2-ethylhexyl isostearate and isotridecyl isononanoate.
  • hydrocarbons paraffin oil, squalane and squalene can be used advantageously for the purposes of the present invention.
  • the oil phase can advantageously also contain cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
  • Such silicones or silicone oils can be present as monomers, which are generally characterized by structural elements, as follows:
  • silicon atoms can be substituted with the same or different alkyl radicals and / or aryl radicals, which here are generally represented by the radicals R 1 - R 4 are shown (to say that the number of different residues is not necessarily limited to up to 4), m can assume values from 2 to 200,000.
  • n can have values from 3/2 to 20. Broken values for n take into account that there may be odd numbers of siloxyl groups in the cycle.
  • Cyclomethicone e.g. decamethylcyclopentasiloxane
  • silicone oils can also be used advantageously for the purposes of the present invention, for example undecamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane), cetyldimethicone, behenoxydimethicone.
  • silicone oils of a similar constitution to the compounds described above, the organic side chains of which are derivatized, for example polyethoxylated and / or polypropoxylated.
  • these include, for example, polysiloxane-polyalkyl-polyether copolymers such as the cetyl-dimethicone copolyol, the (cetyl-dimethicone copolyol (and) polyglyceryl-4-isostearate (and) hexyl laurate)
  • Mixtures of cyclomethicone and isotridecyl isononanoate, cyclomethicone and 2-ethylhexyl isostearate are also particularly advantageous.
  • the aqueous phase of the preparations according to the invention advantageously advantageously contains alcohols, diols or polyols of low C number, and also their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or - monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether , Diethy- glycol monomethyl or monoethyl ether and analog products, furthermore alcohols of low C number, for example Ethanol, isopropanol, 1,2-propanediol, glycerol and in particular one or more thickeners, which one or more can advantageously be selected from the group consisting of silicon dioxide and aluminum silicates.
  • alcohols, diols or polyols of low C number and also their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol,
  • Preparations according to the invention which are present as emulsions particularly advantageously contain one or more hydrocolloids.
  • hydrocolloids can advantageously be selected from the group of the gums, polysaccharides, cellulose derivatives, phyllosilicates, polyacrylates and / or other polymers.
  • Preparations according to the invention which are present as hydrogels contain one or more hydrocolloids. These hydrocolloids can advantageously be selected from the aforementioned group.
  • Gums include plant or tree sap that harden in the air and form resins or extracts from aquatic plants. Gum arabic, carob flour, tragacanth, karaya, guar gum, pectin, gellan gum, carrageenan, agar, alginine, chondrus, xanthan gum can advantageously be selected from this group for the purposes of the present invention.
  • derivatized gums such as e.g. Hydroxypropyl guar (Jaguar® HP 8).
  • the polysaccharides and derivatives include, for example, hyaluronic acid, chitin and chitosan, chondroitin sulfates, starch and starch derivatives.
  • the cellulose derivatives include, for example, methyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose.
  • Layered silicates contain naturally occurring and synthetic clays such as Montmorillonite, bentonite, hectorite, laponite, magnesium aluminum silicates such as Veegum®. These can be used as such or in a modified form such as e.g. Stearylalkonium hektorite.
  • silica gels can also advantageously be used.
  • the polyacrylates include e.g. Carbopol types from Goodrich (Carbopol 980, 981, 1382, 5984, 2984, EDT 2001 or Pemulen TR2).
  • polymers e.g. Polyacrylamides (Seppigel 305), polyvinyl alcohols, PVP, PVP / VA copolymers, polyglycols.
  • Preparations according to the invention in the form of emulsions contain one or more emulsifiers.
  • emulsifiers can advantageously be selected from the group of nonionic, anionic, cationic or amphoteric emulsifiers.
  • nonionic emulsifiers are a) partial fatty acid esters and fatty acid esters of polyhydric alcohols and their ethoxylated derivatives (e.g. glyceryl monostearates, sorbitan stearates, glyceryl stearyl citrates, sucrose stearates) b) ethoxylated fatty alcohols and fatty acids c) ethoxylated fatty amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, e.g. Triton X)
  • polyhydric alcohols and their ethoxylated derivatives e.g. glyceryl monostearates, sorbitan stearates, glyceryl stearyl citrates, sucrose stearates
  • ethoxylated fatty alcohols and fatty acids ethoxylated fatty amides, fatty acid glycol
  • the anionic emulsifiers include a) soaps (e.g. sodium stearate) b) fatty alcohol sulfates c) mono-, di- and trialkylphosphonic acid esters and their ethoxylates
  • the cationic emulsifiers include a) quaternary ammonium compounds with a long-chain aliphatic radical, for example distearyldimonium chloride
  • amphoteric emulsifiers include a) alkylamininoalkane carboxylic acids b) betaines, sulfobetaines c) imidazoline derivatives
  • emulsifiers which include beeswax, wool wax, lecithin and sterols.
  • O / W emulsifiers can, for example, advantageously be chosen from the group of polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated products, for example: the fatty alcohol ethoxylates of the ethoxylated wool wax alcohols, the polyethylene glycol ethers of the general formula RO - (- CH 2 -CH 2 -O- ) n -R ⁇ of the fatty acid ethoxylates of the general formula
  • RO - (- CH 2 -CH 2 -O-) n -CH 2 -COOH and n represent a number from 5 to 30, the polyoxyethylene sorbitol fatty acid esters, the alkyl ether sulfates of the general formula RO - (- CH 2 -CH 2 -O-) n -SO 3 -H of the fatty alcohol propoxylates of the general formula RO - (- CH 2 -CH (CH 3 ) -O-) n -H, the polypropylene glycol ether of the general formula RO - (- CH 2 -CH (CH 3 ) -O-) n-R ', the propoxylated wool wax alcohols, the etherified fatty acid propoxylates R-COO - (- CH 2 -CH (CH 3 ) -O-) n -R ', the esterified fatty acid propoxylates of the general formula R-COO - (- CH 2 -CH (CH 3
  • the polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated O / W emulsifiers selected are particularly advantageously selected from the group of substances with HLB values of 11-18, very particularly advantageously with HLB values of 14.5-15. 5, provided the O / W emulsifiers have saturated radicals R and R '. Do the O / W emulsifiers have unsaturated radicals R and / or R ', or are Isoalkyl derivatives before, the preferred HLB value of such emulsifiers can also be lower or higher.
  • fatty alcohol ethoxylates from the group of the ethoxylated stearyl alcohols, cetyl alcohols, cetylstearyl alcohols (cetearyl alcohols).
  • cetyl alcohols cetylstearyl alcohols
  • cetearyl alcohols cetearyl alcohols
  • the sodium laureth-11 carboxylate can advantageously be used as the ethoxylated alkyl ether carboxylic acid or its salt.
  • Sodium laureth 1-4 sulfate can advantageously be used as alkyl ether sulfate.
  • Polyethylene glycol (30) cholesteryl ether can advantageously be used as the ethoxylated cholesterol derivative.
  • Polyethylene glycol (25) soyasterol has also proven itself.
  • polyethylene glycol glycerol fatty acid esters from the group polyethylene glycol (20) glyceryl laurate, polyethylene glycol (21) glyceryl laurate, polyethylene glycol (22) glyceryl laurate, polyethylene glycol (23) glyceryl laurate, polyethylene glycol (6) glyceryl capate / polyethylene glycol ) glyceryl oleate, polyethylene glycol (20) glyceryl isostearate, polyethylene glycol (18) glyceryl oleate / cocoate.
  • sorbitan esters from the group consisting of polyethylene glycol (20) sorbitan monolaurate, polyethylene glycol (20) sorbitan monostearate, polyethylene glycol (20) sorbitan monoisostearate, polyethylene glycol (20) sorbitan monopalmitate, polyethylene glycol (20) sorbitan monooleate.
  • W / O emulsifiers that can be used are: fatty alcohols with 8 to 30 carbon atoms, monoglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18, carbon atoms, diglycerol esters saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 C atoms, monoglycerol ethers saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12 - 18 C - Atoms, diglycerin ethers of saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12-18 C atoms, propylene glycol esters of saturated and / or unsaturated, branched and atom
  • W / O emulsifiers are glyceryl monostearate, glyceryl monoisostearate, glyceryl monomyristate, glyceryl monooleate, diglyceryl monostearate, diglyceryl monoisostearate, propylene glycol monostearate, propylene glycol monoisostearate, propylene glycol mono capitanium sorbate, sorbitol sorbitol, sorbitol mono-sorbitol, sorbitol monocaprylate, sorbitan monoisooieate, sucrose distearate, cetyl alcohol, stearyl alcohol, arachidyl alcohol, behenyl alcohol, isobehenyl alcohol, selachyl alcohol, chimyl alcohol, polyethylene glycol (2) stearyl ether (steareth-2), glyceryl monylurolate, glyceryl monylurolate,.
  • Example 2 The components of the oil phase are combined and homogenized, then combined with the water phase and brought to a temperature of 80-85 ° C (ie, in the phase inversion temperature range of the system), then cooled to room temperature (i.e. brought out of the phase inversion temperature range of the system) ,
  • Example 2 The components of the oil phase are combined and homogenized, then combined with the water phase and brought to a temperature of 80-85 ° C (ie, in the phase inversion temperature range of the system), then cooled to room temperature (i.e. brought out of the phase inversion temperature range of the system) , Example 2
  • Example 3 The components of the oil phase are combined and homogenized, then combined with the water phase and brought to a temperature of 80-85 ° C (ie, in the phase inversion temperature range of the system), then cooled to room temperature (i.e. brought out of the phase inversion temperature range of the system) ,
  • Example 3 The components of the oil phase are combined and homogenized, then combined with the water phase and brought to a temperature of 80-85 ° C (ie, in the phase inversion temperature range of the system), then cooled to room temperature (i.e. brought out of the phase inversion temperature range of the system) , Example 3
  • Example 4 The components of the oil phase are combined and homogenized, then combined with the water phase and brought to a temperature of 80-85 ° C (ie, in the phase inversion temperature range of the system), then cooled to room temperature (i.e. brought out of the phase inversion temperature range of the system) ,
  • Example 4 The components of the oil phase are combined and homogenized, then combined with the water phase and brought to a temperature of 80-85 ° C (ie, in the phase inversion temperature range of the system), then cooled to room temperature (i.e. brought out of the phase inversion temperature range of the system) , Example 4
  • Example 5 The components of the oil phase are combined and homogenized, then combined with the water phase and brought to a temperature of 80-85 ° C (ie, in the phase inversion temperature range of the system), then cooled to room temperature (i.e. brought out of the phase inversion temperature range of the system) ,
  • Example 5 The components of the oil phase are combined and homogenized, then combined with the water phase and brought to a temperature of 80-85 ° C (ie, in the phase inversion temperature range of the system), then cooled to room temperature (i.e. brought out of the phase inversion temperature range of the system) , Example 5
  • Example 6 The components of the oil phase are combined and homogenized, then combined with the water phase and brought to a temperature of 80-85 ° C (ie, in the phase inversion temperature range of the system), then cooled to room temperature (i.e. brought out of the phase inversion temperature range of the system) ,
  • a temperature of 80-85 ° C ie, in the phase inversion temperature range of the system
  • room temperature i.e. brought out of the phase inversion temperature range of the system
  • Example 7 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 7 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • the respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 10 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 10 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 11 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 11 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • the respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 13 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 13 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 14 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 14 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 15 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 15 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 17 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 17 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 18 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 18 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 19 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 19 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 20 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 20 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 21 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 21 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 22 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 22 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 23 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 23 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 24 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 24 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 25 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • Example 25 The respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • the respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.
  • the respective components of the oil or water phase are combined, the two phases are combined and homogenized at 70-75 ° C. and then cooled to room temperature.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation de combinaisons d'agents actifs composées (a) d'acide α-liponique et (b) d'une ou plusieurs substances dermatologiquement acceptables présentant une absorption de lumière dans la gamme des UV-A et UV-B, pour la fabrication de préparations cosmétiques et dermatologiques destinées au traitement et/ou à la prophylaxie des symptômes du vieillissement intrinsèque et/ou extrinsèque de la peau et au traitement et à la prophylaxie des effets néfastes du rayonnement ultraviolet sur la peau.
EP02729959A 2001-03-06 2002-03-05 Utilisation de combinaisons d'agents actifs composees d'acide alpha-liponique et de substances dermatologiquement acceptables presentant une absorption de lumiere dans la gamme des uv-a et uv-b, pour la fabrication de preparations cosmetiques et dermatologiques Withdrawn EP1367987A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10111039 2001-03-06
DE10111039A DE10111039A1 (de) 2001-03-06 2001-03-06 Verwendung von Wirkstoffkombinationen aus alpha-Liponsäure und dermatologisch verträglichen Substanzen, die Lichtabsorption im UV-A-Bereich und/oder UV-B-Bereich zeigen, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe der Symptome der intrinsischen und/oder extrinsischen Hautalterung sowie zur Behandlung und Prophylaxe der schädlichen Auwirkungen ultravioletter Strahlung auf die Haut
PCT/EP2002/002374 WO2002069925A2 (fr) 2001-03-06 2002-03-05 UTILISATION DE COMBINAISONS D'AGENTS ACTIFS COMPOSEES D'ACIDE α-LIPONIQUE ET DE SUBSTANCES DERMATOLOGIQUEMENT ACCEPTABLES PRESENTANT UNE ABSORPTION DE LUMIERE DANS LA GAMME DES UV-A ET UV-B, POUR LA FABRICATION DE PREPARATIONS COSMETIQUES ET DERMATOLOGIQUES

Publications (1)

Publication Number Publication Date
EP1367987A2 true EP1367987A2 (fr) 2003-12-10

Family

ID=7676657

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02729959A Withdrawn EP1367987A2 (fr) 2001-03-06 2002-03-05 Utilisation de combinaisons d'agents actifs composees d'acide alpha-liponique et de substances dermatologiquement acceptables presentant une absorption de lumiere dans la gamme des uv-a et uv-b, pour la fabrication de preparations cosmetiques et dermatologiques

Country Status (5)

Country Link
US (1) US20040131564A1 (fr)
EP (1) EP1367987A2 (fr)
JP (1) JP2004519483A (fr)
DE (1) DE10111039A1 (fr)
WO (1) WO2002069925A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230053A1 (de) * 2002-07-04 2004-01-15 Beiersdorf Ag Kosmetische oder dermatologische Formulierungen zur Pflege der Gesichtshaut
DE10230060A1 (de) * 2002-07-04 2004-01-22 Beiersdorf Ag Kosmetische oder dermatologische Formulierungen zur Pflege der Gesichtshaut
DE102005022961B4 (de) * 2005-05-19 2007-04-19 Andreas Hentschel Verfahren zum bivalenten Betreiben von Verbrennungsmotoren mit konventionellen Kraftstoffen und Druckgas
JP5023311B2 (ja) * 2005-11-06 2012-09-12 ビーエイチエヌ株式会社 皮膚障害の改善及び／又は予防のための組成物
JP4970805B2 (ja) * 2006-02-22 2012-07-11 株式会社コーセー 皮膚外用剤
FR2936706B1 (fr) * 2008-10-08 2010-12-17 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un compose dithiolane ; procede de photostabilisation du derive de dibenzoylmethane
FR2959125B1 (fr) * 2010-04-22 2012-05-25 Oreal Procede de traitement photoprotecteur des fibres keratiniques par une emulsion eau-dans-huile a base d'un filtre benzylidene camphre hydrosoluble
WO2011160844A1 (fr) * 2010-06-25 2011-12-29 G. Pohl-Boskamp Gmbh & Co. Kg Agent de traitement d'états pathologiques cutanés
JP5952047B2 (ja) * 2012-03-23 2016-07-13 株式会社マンダム 水中油型乳化組成物及び水中油型乳化組成物の製造方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144325A (en) * 1976-11-10 1979-03-13 Voyt Walter F Method of and composition for preventing sunburn while affording tanning
US4248861A (en) * 1979-02-21 1981-02-03 Schutt Steven R Skin treatment methods
DE3314742A1 (de) * 1983-04-23 1984-10-25 Degussa Ag, 6000 Frankfurt An der oberflaeche modifizierte natuerliche oxidische oder silikatische fuellstoffe, ein verfahren zur herstellung und deren verwendung
JPS63233912A (ja) * 1986-12-30 1988-09-29 チャールス　オブ　ザ　リッツ　グループ　リミテッド 紫外線吸収性化合物および遮光剤
JPH03193778A (ja) * 1989-12-25 1991-08-23 Nisshin Oil Mills Ltd:The リポ酸誘導体
DE4242876C2 (de) * 1992-12-18 1997-11-27 Beiersdorf Ag Kosmetische und/oder dermatologische Zubereitungen zur kosmetischen und/oder dermatologischen Pflege der Haut und/oder der Hautanhangsgebilde
JPH10501817A (ja) * 1994-06-15 1998-02-17 ザ、プロクター、エンド、ギャンブル、カンパニー 哺乳動物皮膚における色素過剰部位のライトニング方法
US5472698A (en) * 1994-12-20 1995-12-05 Elizabeth Arden Co., Division Of Conopco, Inc. Composition for enhancing lipid production in skin
US5821237A (en) * 1995-06-07 1998-10-13 The Procter & Gamble Company Compositions for visually improving skin
US5948416A (en) * 1995-06-29 1999-09-07 The Procter & Gamble Company Stable topical compositions
US5709868A (en) * 1995-09-20 1998-01-20 Perricone; Nicholas V. Lipoic acid in topical compositions
DE19548016A1 (de) * 1995-12-21 1997-06-26 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen in Form von O/W-Makroemulsionen, O/W-Mikroemulsionen oder O/W/O-Emulsionen mit einem Gehalt an in gelöster Form vorliegenden, an sich schwerlöslichen UV-Filtersubstanzen, insbesondere Triazinderivaten
DE19601104A1 (de) * 1996-01-13 1997-07-17 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzzubereitungen mit einem Gehalt an Triazinderivaten und Alkancarbonsäuren
DE19602619C2 (de) * 1996-01-25 1998-08-27 Beiersdorf Ag Stabile kosmetische und dermatologische Lichtschutzzubereitungen in Form von W/O-Emulsionen, enthaltend ein Triazinderivat, einen oder mehrere spezielle(n) W/O-Emulgator(en) und/oder weitere Komponenten
DE19631222C2 (de) * 1996-08-02 1998-11-12 Beiersdorf Ag Stabile Lichtschutzzubereitungen mit einem Gehalt an grenzflächenaktiven Glucosederivaten und wasserlöslichen UV-Filtersubstanzen
DE19754037B4 (de) * 1997-12-05 2005-03-03 Beiersdorf Ag Verwendung von Polysacchariden zur Verbesserung der Lichtschutzwirkung kosmetischer oder dermatologischer Lichtschutzmittel
IT1313595B1 (it) * 1999-08-03 2002-09-09 Giorgio Panin Dispositivo per erogazione spray di una composizione per applicazionetopica comprendente vitamina e e acidi grassi essenziali.
JP3461769B2 (ja) * 1999-11-26 2003-10-27 株式会社ノエビア 皮膚外用剤
US20020044913A1 (en) * 2000-02-11 2002-04-18 Hamilton Nathan D. Cosmetics to support skin metabolism
PT1294353E (pt) * 2000-06-06 2006-07-31 Basf Ag Utilizacao do enantiomero (r) do acido lipoico em composicoes cosmeticas e dermatologicas
DE10036797A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Verwendung von Kombinationen mit einem Gehalt an Carnitinen
AU2001238511A1 (en) * 2000-08-07 2002-02-18 Juvenon, Inc. Cosmetics to support skin metabolism
US20020119114A1 (en) * 2000-12-18 2002-08-29 Beiersdorf Aktiengesellschaft Active ingredient combinations of surface-active citric esters and alpha-lipoic acid, and cosmetic and dermatological preparations containing such mixtures

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02069925A2 *

Also Published As

Publication number Publication date
US20040131564A1 (en) 2004-07-08
WO2002069925A2 (fr) 2002-09-12
JP2004519483A (ja) 2004-07-02
WO2002069925A3 (fr) 2003-02-13
DE10111039A1 (de) 2002-09-12

Similar Documents

Publication Publication Date Title
DE10356164A1 (de) Wirkstoffkombinationen aus Licochalcon A oder einem Extrakt aus Radix Clycyrrhizae inflatae, enthaltend Licochalcon A, Phenoxyethanol und gewünschtenfalls Glycerin
WO2005053680A1 (fr) Association de 2,3-dibenzylbutyrolactone et de licochalcone-a
DE10356187A1 (de) Wirkstoffkombinationen aus Phytosterolen und/oder Cholesterin und Licochalcon A oder einem wäßrigen Extrakt aus Radix Glycyrrhizae inflatae, enthaltend Licochalcon A
EP1367987A2 (fr) Utilisation de combinaisons d'agents actifs composees d'acide alpha-liponique et de substances dermatologiquement acceptables presentant une absorption de lumiere dans la gamme des uv-a et uv-b, pour la fabrication de preparations cosmetiques et dermatologiques
EP1395239A1 (fr) Compositions cosmetiques ou dermatologiques contenant une ou plusieurs cetohexoses
EP1676571A1 (fr) Composition comprenant au moins un isoflavone et du carnitine et/ ou au moins un acyl-carnitine
WO2003015766A1 (fr) Utilisation de wogonine pour fabriquer des preparations cosmetiques ou dermatologiques destinees a la prophylaxie et au traitement d'etats inflammatoires cutanes et / ou a la protection de la peau en cas de peau sensible et seche
WO2003015737A1 (fr) Utilisation d'oroxyline a pour fabriquer des preparations cosmetiques ou dermatologiques destinees a la prophylaxie et au traitement d'etats inflammatoires cutanes et / ou a la protection de la peau en cas de peau sensible et seche
DE10111048A1 (de) Verwendung von alpha-Liponsäure zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Regeneration beanspruchter Haut, insbesondere der gealterten Haut
EP1368026A1 (fr) Utilisation de combinaisons de principes actifs issues d'acide alpha-lipoique et de substances absorbant la lumiere dans la plage des uv-a ou des uv-b pour traiter et/ou assurer la prophylaxie de pigmentation cutanee indesirable
DE10140538A1 (de) Verwendung von wässrig-alkoholischen Extrakten aus Pongamia pinnata zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
DE10140539A1 (de) Verwendung von wässrig-alkoholischen Extrakten aus Terminalia arjuna zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
DE10148266A1 (de) Verwendung von Mevalonsäure und/oder Mevalonsäurelacton zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe der Symptome der intrinsischen und/oder extrinsischen Hautalterung sowie zur Behandlung und Prophylaxe der schädlichen Auswirkungen ultravioletter Strahlung auf die Haut
WO2002069911A2 (fr) Combinaisons de principes actifs, reunissant de l'acide $g(a)-lipoique et des bioquinones
WO2003101407A1 (fr) Utilisation d'extrait de fleur de chevrefeuille dans la production de preparations cosmetiques ou dermatologiques de prophylaxie et traitement d'etats cutanes inflammatoires et/ou de protection pour peau sensible
DE10217256A1 (de) Kosmetische und dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Phytochelatinen
DE10121090A1 (de) Wirkstoffkombinationen aus Tetrahydrocurcuminoiden und Sericosid und/oder Pflanzenextrakten
DE102005019549A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Diaminobenzimidazol
DE10126396A1 (de) Verwendung von Glucosamin zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter und trockener Haut
DE10111047A1 (de) Verwendung von Wirkstoffkombinationen aus alpha-Liponsäure und Dermatologisch verträglichen Substanzen, die Lichtabsorption im UV-A-Bereich und/oder UV-B-Bereich zeigen, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Stärkung der Barrierefunktion der Haut
DE10241889A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Chinolinsäure und/oder ihren Derivaten
DE10213419A1 (de) Verwendung von alkylierten Glucosaminen zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe der Symptome der intrinsischen und/oder extrinsischen Hautalterung sowie zur Behandlung und Prophylaxe der schädlichen Auswirkungen ultravioletter Strahlung auf die Haut
DE10144262A1 (de) Wirkstoffkombinationen aus einer oder mehreren Ascorbylverbindungen und alpha-Liponsäure
DE10121089A1 (de) Wirkstoffkombinationen aus Tetrahydrocurcuminoiden und Substanzen, die verhindern, dass die NO-Synthase des warmblütigen Organismus seine Wirkung entfaltet
DE10252772A1 (de) Verwendung von einem oder mehreren Diethyldithiocarbamaten zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter und trockener Haut

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031006

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

17Q First examination report despatched

Effective date: 20040414

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041026